Tested new HER2-targeted treatment for advanced bowel cancer after failure
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 2 study tests a combination of anti-cancer drugs for HER2-positive or HER2-mutated advanced colorectal (bowel) cancer after standard treatment has failed or you couldn’t tolerate it. It aims to see if this treatment can better control the cancer and shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old with advanced colorectal cancer
- Your cancer has HER2 amplification or an HER2 mutation confirmed by lab testing
- You tried standard first-line treatment and it either failed or you couldn’t tolerate it
- Your scans show at least one measurable tumor spot that can be followed over time
- You are well enough to do daily activities (ECOG 0–1) and you expect to live at least 12 weeks
- Your blood counts, liver/kidney function, and heart ultrasound/ECG meet safety limits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, zanidatamab and tislelizumab, for people with HER2-positive gastrointestinal tumors, including stomach, gastroesophageal junction, and colorectal cancers. The goal is to see if this treatment can shrink or control the cancer.
This trial tests a combination of two targeted drugs (against HER2 and EGFR) plus chemotherapy for people with a specific type of advanced colorectal cancer that has spread and stopped responding to standard treatments. It aims to see if this new approach can shrink tumors or slow the cancer's growth.
This trial tests a combination of two drugs (sintilimab and pyrotinib) with or without chemotherapy for people with advanced digestive system cancers that have a specific marker called HER2. The goal is to see if this combination can shrink tumors or stop them from growing.
This Phase 2 trial studies whether adding tislelizumab to standard chemo (CAPOX) around the time of surgery can lower the risk of colon or rectal cancer coming back. It’s for people with stage II or III tumors that have an MSI-H or dMMR test result, which may mean they’re more likely to respond to immune-based treatment.
This trial tests an injection called TQB2102 for people with advanced colorectal cancer that has a specific marker called HER2 IHC3+. If you have tried at least two standard treatments and they stopped working or caused side effects, this study may be an option.
This study tests a treatment approach for stomach cancer that hasn't spread to other organs. It's for people who have not had any prior cancer treatments and are in relatively good health.
Hear when a new HER2-positive or Mutated Advanced Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.